Increasing reports from patients suggest Ozempic may lead to permanent vision loss

Weight loss medications, particularly Ozempic, have become incredibly popular, being used for various conditions, including diabetes and weight management.

However, an increasing number of patients are expressing concern that Ozempic may have a serious side effect: irreversible vision loss.

Edward Fanelli, a former contractor from Freehold, New Jersey, shared that he was prescribed Ozempic for his diabetes management. Unfortunately, he experienced sudden vision problems that forced him to leave his job.

“Not even six to eight months later, I suddenly lost sight in my right eye,” he recalls. “I couldn’t risk doing contracting work because I was worried about injuries.”

He was diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), a condition that appears suddenly and has no cure. Fanelli is the first individual in New Jersey to sue the manufacturers of Ozempic, citing that he was never informed about the possibility of irreversible vision loss.

“If they had told me there was a chance I could lose my vision, I wouldn’t have taken it. I wouldn’t care; I could have managed weight loss on my own,” he remarked.

Fanelli is not the only one with such issues.

Attorney Jason Goldstein from Long Island represents more than a dozen clients, including Fanelli, in lawsuits alleging that semaglutide, the active component in Ozempic and similar drugs, has been linked to NAION in medical literature.

Goldstein claims the pharmaceutical companies did not adequately inform patients about these risks.

“The main point of this case is that people were not warned. What did the doctors know? What did the patients know? No one was informed,” he stated.

He plans to advocate for better warning labels and compensation, to prevent future patients from facing similar issues from a medication they believed would be helpful.

A spokesperson for Novo Nordisk issued a statement:

“NAION is an extremely rare eye condition, and it is not recognized as an adverse reaction for semaglutide (Ozempic®, Rybelsus®, and Wegovy®) based on approved labels. Following a comprehensive review of studies from the University of Southern Denmark and our internal safety assessments, we maintain that the benefit-risk profile of semaglutide remains unchanged.

Novo Nordisk has conducted analyses through randomized controlled trials with GLP-1 receptor agonists, including evaluations by ophthalmologists to confirm NAION diagnoses. The data does not indicate a causal link between the use of GLP-1 RA and NAION events.

Patient safety is our utmost priority, and we take all reports of adverse events linked to our medications very seriously, including eye conditions, which are known to be common issues for individuals with diabetes. Any decision regarding treatment with prescription-only medications should involve a healthcare professional who can evaluate the benefits and risks for the patient in question.”

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News